Reduction of inappropriate medication in older populations by electronic decision support (the PRIMA-eDS study): a qualitative study of practical implementation in primary care
Within the EU-funded project PRIMA-eDS (Polypharmacy in chronic diseases: Reduction of Inappropriate Medication and Adverse drug events in older populations by electronic Decision Support) an electronic decision support tool (the “PRIMA-eDS-tool”) was developed for general practitioners (GPs) to reduce inappropriate medication in their older polypharmacy patients. After entering patient data relevant to prescribing in an electronic case report form the physician received a comprehensive medication review (CMR) on his/her screen displaying recommendations regarding missing indications, necessary laboratory tests, evidence-base of current medication, dose adjustments for renal malfunction, potentially harmful drug-drug interactions, contra-indications, and possible adverse drug events. We set out to explore the usage of the PRIMA-eDS tool and the adoption of the recommendations provided by the CMR to optimise the tool and prepare it for its future implementation.
In a qualitative study carried out in North Rhine-Westphalia, Germany, 21 GPs using the PRIMA-eDS tool within the PRIMA-eDS study were interviewed. Interviews encompassed the GPs’ attitudes regarding use of the electronic case report form and the CMR, their response to the recommendations, and the implementation of the tool into daily practice routine. The collected data were analysed applying thematic qualitative text analysis.
GPs found the patient data entry into the electronic case report form to be inconvenient and time-consuming. The CMR was conducted often outside practice hours and without the patient present. GPs found that the PRIMA-eDS CMR provided relevant information for and had several positive effects on the caring process. However, they encountered several barriers when wanting to change medication.
It is unlikely that the PRIMA-eDS CMR will be used in the future as it is now as patient data entry is too time-consuming. Several barriers towards deprescribing medications were found which are common in deprescribing studies. Given the positive attitude towards the CMR, a new way of entering patient data into the PRIMA-eDS tool to create the CMR needs to be developed.
KeywordsGeneral practitioner Evidence-based medicine Computerized clinical decision support system Deprescribing Perceptions Aged
Computerised decision support system
Comprehensive medication review
Electronic case-report form
Electronic health record
Polypharmacy in chronic diseases: Reduction of Inappropriate Medication and Adverse drug events in older populations by electronic Decision Support
The geriatric population is growing in Europe . Providing excellent care for older people with multimorbidity (i.e. multiple coexisting diseases in the same individual ) is complex and poses a challenge to general practitioners (GPs) in their daily routine [3, 4]. This challenge results from the many care components that need to be considered in a limited consultation time  in addition to the fact that easily accessible information on appropriate treatment in multimorbidity is lacking . In order to treat multiple diseases physicians frequently prescribe several drugs. Taking a number of medications is known as polypharmacy , though exact definitions vary across the literature . Polypharmacy can be problematic as it increases the risk of medication errors and may lead to adverse effects such as drug-related hospitalisations [7, 8].
Several strategies to optimise medication have been developed and tested in various settings over the past years, which can be divided into explicit or criterion-based measures (such as the Beers criteria ), implicit or judgment-based measures (such as the medication appropriate index ), and tools combining both approaches (such as the Australian Prescribing Indicators ) . Such interventions have demonstrated improvements in appropriate polypharmacy and reductions in inappropriate prescribing, however, evidence for significant improvements of clinically relevant endpoints such as mortality or hospitalisations remains unclear [13, 14, 15, 16]. There is a need to develop further strategies and to test them in large randomised controlled trials that have sufficient power to detect clinically relevant outcomes, and besides, asses the feasibility of the use of the strategies .
Within the health care system, an ideal point to optimise a patient’s medication is primary care . However, many GPs feel uncertain about dealing with their multimorbid, older patients and desire more precise information about the benefits and risks of drugs and about patient relevant outcomes [3, 4, 18, 19]. A further difficulty is to deal with disease-specific guidelines as GPs feel uncertain about applying guidelines which focus on single diseases and often do not take the older age or the complexity of multimorbidity into account . Besides, routines for assessing medication plans regularly do not exist . Studies show that physicians would appreciate support to manage complex information , such as provided by computerised decision support systems (CDSS) .
CDSS have the capacity to help clinicians process complex clinical information . Over the years, many different CDSS have been developed with some of them showing improved outcomes such as a reduction of serious medication errors and an increase in adhering to guidelines . However, there have also been problems with CDSS such as the overriding of highly important alerts due to alert fatigue . Besides, the mere provision of a CDSS does not guarantee its uptake. A systematic review on factors impacting on CDSS for prescribing concluded that there is no universal approach to successful CDSS implementation. Factors influencing the use and adoption relate to organisational factors such as the infrastructure and implementation, provider-related factors such as knowledge, training, current practice and preferences, patient-related factors such as patient and doctor-patient characteristics, and issues specific to the CDSS such as integration into the workflow .
An indication check for all prescribed medications according to the diagnoses provided in the eCRF.
A summary of laboratory test results that are relevant for the appropriate and safe use of the drugs on the medication list, and alerts if a result is outside recommended limits or if a repeat measurement may be due.
Suggested evidence-based recommendations related to the medication. These can include, but are not limited to recommendations on: discontinuing drugs where there is no evidence for a positive risk/benefit balance, or where evidence points out that risks may outweigh benefits in older people; discontinuing drugs that are on lists of potentially inappropriate drugs for older people (PIM lists), such as the EU(7)-PIM list ; discontinuing drugs that have been used for a longer period than recommended in guidelines; discontinuing drugs that are not indicated on the basis of a small or questionable anticipated effect; ordering follow-up laboratory tests for monitoring and improving patient safety.
Alerts related to drug prescribing in cases of renal malfunction.
Alerts about known potentially harmful interactions between the patient’s drugs.
Alerts about contraindications in case the patient has a recorded diagnosis that is a contraindication for one of his/her current drugs.
Dose warnings in case daily doses exceed the recommended maximal levels according to the indication provided.
A table listing the risks of nine standard adverse effects (anticholinergic effect, risk of bleeding, constipation, orthostatic dysregulation, QT-prolongation, renal toxicity, sedation, risk of seizures, serotonergic effect) possibly associated with each current drug.
It is important to understand usage and acceptance of the PRIMA-eDS tool in order to optimise it so that it can be implemented into routine primary care practice, provided that it is effective and cost-effective. This exploratory study examines how GPs experienced the use of the PRIMA-eDS tool, how GPs adopted the recommendations provided by the CMR, and explores GPs’ ideas on the future implementation of the tool.
An exploratory study design based on semi-structured interviews was adopted to gather an in-depth understanding of GPs’ experiences with the PRIMA-eDS tool. We report this study according to the Consolidated Criteria for Reporting Qualitative Research (COREQ) guidelines .
Recruitment and data collection
We conducted in-depth interviews with GPs belonging to the intervention group of the PRIMA-eDS study centre of Witten/Herdecke University, Germany. GPs from the study centre Witten/Herdecke University come from cities and rural areas of the Ruhr valley in North Rhine-Westphalia, Germany. In total, the PRIMA-eDS study centre Witten/Herdecke University comprises 76 GP practices and 35 of them belong to the intervention group. GPs had been participating in the PRIMA-eDS study for up to 1 year when being invited. Using a random order list, we invited all GPs that had used the PRIMA-eDS tool at least twice. Semi-structured interviews with open-ended questions were undertaken to explore the use of the PRIMA-eDS tool and gather ideas on how the tool could be implemented into daily practice routine. We followed the concept of information power  and carried out interviews until we had sufficient information power fitting to the aim and analysis of our study as well as to our sample specificity and the generated quality of dialogue. Three interviewers with different backgrounds were trained and carried out the interviews: a research assistant of the PRIMA-eDS project with a master in public health (AR), a medical doctor working for PRIMA-eDS (CS), and a medical student with a bachelor in health communication who was not involved otherwise in the PRIMA-eDS study. All interviewers were not familiar with the participants. At the start of each interview, it was made clear that the interviewers were independent and that opinions in all directions could be expressed without any consequences. The interviews were carried out in the GPs’ own offices as this provided the GPs’ familiar surroundings where we expected the GPs to feel comfortable and open to talk about their experiences on a personal level. Furthermore, in this way we avoided possible travel-related burden for the interviewees.
Interview guide main questions
1. Polypharmacy in everyday practice (Icebreaker)
Which role do polypharmacy patients play in your daily practice?
2. Using the eCRF
You have entered [number of] patients, what experiences did you have with the eCRF?
3. General overview of the CMR
What are your experiences with the PRIMA-eDS CMR?
4. Output of the CMR and how GPs responded to the recommendations
Going through the CMR of one of the GP’s patient
What do you think about the various sections?
What happens between reading the recommendations and the moment of discontinuing medication?
How did the CMR influence you in treating your patients?
5. Implementation of the PRIMA-eDS tool into daily practice routine
Which benefits/barriers do you see in using the PRIMA-eDS tool in the future?
Do you have any recommendations for further development?
Characteristics of GPs (N = 21)
Age (in years)
Years in practice*
Working in a single-handed practice
Number of patients included in the main trial
Interviews were recorded, anonymised and transcribed verbatim. For the analysis, all interviews were taken into account at full length. Thematic qualitative text analysis with an deductive-inductive approach was conducted to analyse the material as described by Kuckartz  consisting of seven steps. First, AR and CS independently read all transcripts and initially worked with the text by highlighting important passages and composing memos. Second, we developed the main topical categories from the interview guide, and third, conducted the first coding process by coding the entire material using the main categories. Fourth, we compiled all passages assigned to each of the main categories, and fifth, determined sub-categories inductively from the material. The sixth step was the second coding process: coding all of the data using the elaborate system. Thereafter, as a seventh step, we conducted a category-based analysis along the main topics. Two coders (AR and CS) independently coded the material. Any differences were solved by discussion. Contradictory data was taken into account. The software MAXQDA 12 was used in the analysis and coding process. Interviews were analysed in German. The coding scheme is presented in Additional file 1.
The study has been approved by the ethics committee of Witten/Herdecke University in July 2015 [no: 92/2015]. Written informed consent was obtained from the participants before the start of each interview. The anonymity and confidentiality of the participants was ensured by coding the participants as numbers (1–21) and by removing all identifiers during the transcribing process and for the presentation of the results. As a possible burden could arise for the GPs participating in the interviews in the form of an increased work and time expenditure, we compensated the time spent by an allowance for expenses. The GPs were able to terminate the interviews at any time, though this did not happen.
We present our results according to the adoption of the intervention: the eCRF, the CMR, the adoption of the recommendations, and future implementation. Selected quotations are presented to illustrate answers from various respondents.
Adoption of the intervention: The eCRF
In the beginning it took a while, but then it went pretty quickly. […] For the first one I took 45 minutes I think and in the end it took me ten minutes. (GP 14).
In the beginning you had to familiarise yourself a bit with this programme first. This required some getting used to it, and for sure the error rate was high at first, too. But somehow in the course of time you learned how to use it. (GP 21).
I added his medication later, without him being there. If you sit there and type something, it can be rather impersonal. I don’t like doing that too much. (GP 14).
I put in the important facts to the best of my knowledge, but I often thought that I didn’t talk about it. (GP 8).
Once or twice I wanted to go back [to the patient in the eCRF], but it said that I can’t. (GP 5).
Adoption of the intervention: The CMR
Sometimes I did it after they left, the next day or the same day or during the break or something like that. Sometimes I did it with the patients, provided they were mentally fit. (GP 16).
I did it after the patient was here. […] I usually make notes and I put them on my desk. Until I discuss them with my patients […] that can take a few days. (GP 17).
On the weekends here. It’s impossible to do it in between the practice hours. […] I printed out the medication plan and noted down what [medication changes] I wanted to discuss. (GP 8).
So, I usually don’t use it in the presence of the patient, but when the patient is present in the practice. When the patient is waiting in the treatment room. Then I call up [the CMR] and then I go to [the patient]. (GP 13).
At home […] because I’m not online here. So I looked through it and then I noted for each patient down the recommendation from your list of suggestions. And then I thought about which of them I should implement and what things I keep in spite of the recommendation from the list. (GP 12).
[I] wrote a memo “change study this to that”. [… I] then put it on my desk, then it takes two, three weeks until eventually I find a small hole and then I changed it. (GP 2).
Experiences with the patient
I discuss it, I propose it [to the patient] and explain that this and that is the reason and that I read this [in the CMR of the] study and explain what could happen, the reason, [and ask] should we give it a try? (GP 2).
Discussing is a bit difficult, it depends, and the thing is that those [patients that are in the study] are mostly not the kind of people that value discussions. […] They don’t like it, they’re not used to discuss extensively why one should […] change something. […] Older people, sick people, they normally accept what one offers them. It rarely happens that they ask ‘why’. (GP 9).
They are happy. Those people who didn’t want something like this; they are simply not part of the study. So, when I tell [the patient] that this medication check recommends this and that, then they are actually quite positive. (GP 7).
Generally, these are older patients and to convince them that certain drugs, that we need to change them, that’s not always easy. […] Patients are anyway quite worried because of these discount contracts [between the pharmaceutical companies and] the health insurances. (GP 18).
The patients, they were really enthusiastic, they enjoyed getting a lot of attention and felt properly checked up, figuratively spoken, concerning their drugs. Those [patients] really left beaming with joy. (GP 15).
Expenditure of time
It [the time required] is relatively little. But on the other hand also still too much for me to do it directly during the daily business. […] If I had to do it by hand, I’d take forever to finish. (GP 17).
That was not time-consuming at all. (GP 11).
In the longer term it is a tool which might tell you for the next patient, man, that’s not a very good combination, so it creates a learning effect as well. Therefore the time spent in relation to the benefit will clearly get better at some point. (GP 1).
Evaluation of the CMR
Prior knowledge pre-existed in many ways, but especially for example with interactions of psychotropic drugs, of neurological drugs, risk of haemorrhage in SSRIs and these things, these are not always that [present]. Risk of falling, especially things which are relevant to older people, that is helpful information for sure. (GP 1).
You can’t possibly have all that in mind and it can be very helpful to be shown everything that you should basically take into consideration. (GP 17).
So I think it’s good to actually think about critical stuff and also to be made aware of it, but […] it is very ‘pacific’ [in the sense of not aggressive enough regarding recommendations to discontinue drugs]. (GP 13).
Adoption of the recommendations
[I] did change quite a bit and also discontinued [some drugs] and it didn’t affect the treatment of the patients negatively. Rather positively, because I tried harder to notice the one or other. (GP 8).
I made changes for almost everyone; I think except for one, I think I’ve changed something based on the recommendation dose reduction with reduced renal functioning. (GP 4).
Mainly small changes. To some extend only in between one group of drugs, for instance simvastatin instead of atorvastatin. One time it was about reducing the dosage by half because of some renal function. I would not rate it that high right now. (GP 12).
Despite the medication check, I could hardly discontinue anything. (GP 13).
Unfortunately that didn’t work. But here I have to say, this really is something where one has to accept it, if one says, there’s no other way. This is of course a deliberate thing. What is important is that one simply always does everything deliberately and that one can justify why one’s doing something. (GP 14).
We also followed that and it actually worked out well. People are also coping fairly well with less or with an adjustment. (GP 8).
I wanted to somehow slowly reduce. It cannot be stopped all of a sudden. (GP 20).
Barriers to adopt recommendations
Barriers to following the recommendations from the GPs’ point of view
Reasons for not following the recommendations
Alternatives and recommendations had already been tested and the GP and/or the patient felt that this was not the optimal way of treatment.
It's a long way making that decision and once it’s made and then it is an important drug. I don’t care if there is a contraindication, he’ll get it nevertheless. (GP 19)
Why in this patient I won’t follow the recommendations is that it has already been tried out in the past. (GP 3)
The GP regarded the medication as being necessary.
Out of the multimorbidity of the people, it is inevitable that one gives them [the drug]. (GP 6)
The GP and/or the patient had other priorities compared to the PRIMA-eDS tool.
Then the patient decides for me. From a certain age on it is about the quality of life. (GP 10)
Concerning diclofenac for the older patients it simply is like that, he just doesn’t want [to discontinue the drug] and says, “you can’t take this away from me. [I am] free of pain for the first time in 7 years. I need that.” (GP 10)
The GP feared that changing medication could get complex.
In case of a patient for whom this medication works so well, in inverted commas, over such a long period of time I won’t change anything. This would just rock the boat. (GP 3)
The GP had been prescribing the medication for years and lacked motivation to reconsider.
And that is simply a drug that the patient is using for 30 years now and under which she is well managed concerning her blood levels. [And] as mentioned leading a life with very little hardship with over 90 years. I would not touch it, that is [a case of] ‘never change a winning team’, therefore these are things I wouldn’t change. (GP 12)
The GP did not want to diverge too far from a standard of therapy (guidelines).
So you have to ultimately stick to the general guidelines, because if you go there now radically, then you contravened the guidelines of the professional societies. It’s difficult. (GP 9)
The GP found the recommendation to be new and not comprehensible.
I’ve never heard that before, it somehow was completely new to me and so I ignored it. (GP 16)
The GP considered the recommendation as not applicable to the individual patient.
Where I say that the patient is biologically younger. (GP 1)
The GP found that the patient was a barrier to discontinue medications.
The patient won’t cooperate. If there wasn’t the patient, everything would be easier. (GP 15)
The prescription was made by another medical specialist and the GP did not want/ did not dare to change it.
Who is responsible for which prescription. The things I do not prescribe, the four medications I do not prescribe, the four psychotropic drugs, I can’t change that. (GP 7)
It seems that due to the infrastructure medication changes resulting from the CMR could have been delayed or even forgotten.
This actually is a relatively long process, as I don’t have internet access here. […] I print it [the CMR] and make notes. […] Then I wait until the patient comes again. But I have [a study patient] who doesn’t come very often and then it's difficult. (GP 2)
One reason was that GPs prioritized differently (e.g. pain relievers) compared to the PRIMA-eDS CMR or regarded medication as necessary and alternatives had already been tested. Sometimes, GPs did not follow recommendations as they feared that changing medication could get complex. Frequently they had been prescribing the medication for years and lacked motivation to reconsider it or did not want to diverge too far from a standard of therapy (guidelines). Sometimes GPs found the new recommendations not comprehensible or considered the recommendations as not applicable to the individual patient who was perceived biologically younger (see Table 3 for quotes).
At times, also the patient was perceived as a barrier. GPs felt that the willingness to change medication depended on the actual medication and priorities of the patient (e.g. pain relievers vs. antihypertensives). GPs reported that sporadically, patients postponed implementing medication changes (e.g. to after a holiday). Furthermore, it was described that some patients faced a dilemma: the wish to take fewer drugs but little willingness to change lifestyle (see Table 3 for quotes).
GPs were reluctant to discontinue medication prescribed by other medical specialists without contacting them. Contacting the specialist to change medication, however, took additional effort and GPs feared that it would be difficult to reach a consensus as the specialists often have a different viewpoint (see Table 3 for quotes).
It seems that a further barrier was that the CMR was sometimes conducted without the patient being present in the practice (e.g. outside of practice hours) and thus medication changes resulting from the CMR could have been delayed or even forgotten.
Other effects resulting from the CMR
Effects of the CMR apart from medication changes
Effects of the CMR
The CMR stimulated GPs to critically reflect on the medication more than usual and to make more conscious decisions.
Of course you engage more intensively with the patient and what he actually has to swallow. (GP 1)
With other things I looked them up again and assured myself. It really is a push to grapple with things again that one should actually be mastering. (GP 18)
The CMR increased GPs’ awareness of risks associated with drug use in polypharmacy patients.
What is good about it, of course, it makes me aware again and again. (GP 4)
The CMR supported GPs in the dialogue with other medical specialists as the CMR provided good evidence for the GPs’ decision.
I can now say that the European study has recommended it. (GP 10)
GPs were able to transfer CMR results to patients outside of the study.
[I] changed quite a bit and also discontinued [some drugs] and it didn’t affect the treatment of the patients negatively. Rather positively, because I tried harder to notice the one or other and also with patients not participating in the study. (GP 8)
The recommendations stimulated the GPs to critically reflect on the medication more than usual and helped to make a more conscious decision. Due to the CMR, the GPs became aware of risks and got a better sense about them. Some recommendations were transferred to patients not participating in the study (see Table 4 for quotes).
The recommendations supported the GPs in the dialogue with other medical specialists and patients as the GPs became more confident and better at explaining the results (see Table 4 for quotes).
It has to be included in every software and then it is easy and then it will also be used. (GP 19).
Nevertheless, according to the GPs, several hindering as well as enhancing factors exist for the future implementation. Many of them have already been named in the sections adoption of the intervention: the eCRF and the CMR.
Possible barriers to the future implementation from the GPs’ perspective
GPs worry that a possible barrier for the future use of the PRIMA-eDS tool could be…
the time required.
If I should benefit from this in any way, it can’t go beyond the limitations of a certain time frame. (GP 12)
the required internet access (for those that are not connected yet).
Well we don’t have any internet access. (GP 9)
possible costs without being reimbursed.
It depends somewhat on the price. (GP 17)
the technical implementation and data security.
Besides [technical problems] none. (GP 5)
If data security is given, none. (GP 3)
Possible enhancing factors for the future implementation from the GPs’ point of view
Possible enhancing factors
GPs consider a strength for the future implementation of the PRIMA-eDS CMR that…
it supports them in optimising medications and improving patient safety.
Yes, in first place patient security. That one really protects the patient from being harmed by drugs. (GP 14)
Certainly reduces mistakes. (GP 10)
it provides a quick way of checking medications.
That one really can quickly control a patients’ [prescriptions], especially when he’s taking multiple drugs or a rare combination, that one then really succeeds in checking during everyday practice. (GP 17)
they can get direct feedback when prescribing a medication for the first time.
I think it’s great. That one might not take the wrong drug when making a new prescription but that one already sees a warning. (GP 8)
it is free of commercial advertisement and independent from the pharmaceutical industry.
Yes, I could imagine [to use it], especially if it's free of commercial advertisements and not sponsored by the pharmaceutical industry. (GP 16)
Our findings suggest that the PRIMA-eDS tool will not be used in daily practice outside of the study as it is too time consuming, especially with regard to entering patient data. On the other hand, GPs really value the CMR to be useful as it summarises important information regarding evidence-based and appropriate drug-treatment and stimulates the GP to critically reflect prescriptions. The GPs interviewed in our study clearly state that they would like to use the CMR in daily practice if the time-consuming entry of patient data were omitted.
Comparison with existing literature
GPs named a multitude of reasons for not following the recommendations. Barriers to deprescribing (i.e. the process of withdrawing medications ) have been widely discussed in the literature. Several studies described the reluctance of GPs to interfere with medication prescribed by a colleague [3, 17, 18, 19, 32, 33, 34]. Furthermore, Schuling et al. showed that stopping a medication is not always easy and depends on the patients’ preferences (especially pain medication). A further barrier is that GPs feel guilty if they do not adhere to guidelines . Some GPs also fear a potential for litigation when deprescribing medication .
In the literature, further barriers to deprescribing medication or using CDSS exist, such as that some GPs feel uncomfortable with reading and communicating measures of risk [18, 35]. These barriers were not brought up in our study. The PRIMA-eDS tool does not use numbers (like absolute or relative risks and numbers needed to treat) in the main message of the recommendations, making an understanding of risks easier. Such numbers were only shown when a GP clicked on a button for “further information”.
We recommended to the GPs to discuss the CMR with their patients in a shared decision-making process and gave instructions on how to do so. Most GPs stated that they involved the patient in the decision-making process of possible medication changes, though it seems that the actual way of discussion varied. Besides, we do not know how satisfied the patients really were as previous studies have shown that even though GPs rated their communication as adequate or very good, patients were not satisfied . While it seems that GPs often involved their patients, it was also raised that there were older patients that did not want to be involved in the decision-making process. Previous research has shown that the desire for a shared decision-making process differs among older people. There are those patients that want to be involved, however, there are also those that do not want to be involved and simply accept the GPs’ decision . Here again, we do not know how satisfied the patients were.
A key issue which was prominent throughout the main categories formed by our analysis was time. Time constraints as a barrier to use CDSS have been widely discussed in the literature [22, 35, 38, 39, 40]. Other barriers for implementing CDSS in the literature were lack of basic IT skills , earlier experience of dysfunctional computer systems in health care, and general resistance towards changes in practice . These factors were not mentioned in our interviews, which might have to do with the selection of GPs and that our study was conducted several years later than most of these other studies.
Implications for future implementation and use
For the implementation of the PRIMA-eDS tool, the whole process of entering patient data needs to become more time efficient. Future developments should focus on linking the CMR to the existing EHR as generally integrated systems are more likely to succeed than “stand alone” systems [22, 41]. This of course requires EHR to be up to date, which often is not the case in daily routine. In Germany, linking EHR to the CMR will not be easy to realise due to the multitude of software providers. Certainly, the CMR will not be able to unfold its full potential in case patient data is not complete or not completely up to date. Still, the CMR can be beneficial even with incomplete data. For instance, if only some medications are entered, the medication check can still be performed for these drugs. On the other hand, incomplete data could also lead to false alerts and reminders or to a lack of necessary alerts. This in turn could compromise the trustworthiness of the system, as encountered by Koskela et al. . Thus, efforts to enhance patient data entry seem indispensable.
The PRIMA-eDS tool can only be used in daily routine when the GP practice is connected with the internet. Even though internet access in GP practices is common in Germany, there are still some practices that do not have it. Due to the ongoing digitalisation in health care systems, we expect that internet access will be available in most practices in the near future. Besides, for the implementation it needs to be ensured that possible costs are remunerated and that data security remains ensured.
Strengths and weaknesses of the study
The GPs participating in this study are a selection of GPs who voluntarily participated in the PRIMA-eDS study as well as in this qualitative investigation. We expect them to be more interested in electronic decision support, the topic of polypharmacy, and to be more engaged compared to their peers. Still, we were able to interview GPs of various ages and different experience levels which provided the possibility to examine a multitude of views and experiences. The interviewed GPs were living in North Rhine-Westphalia, Germany, and thus there are some limitations to the generalisability of findings in other settings. The interviews were conducted within the first year of the study, and thus, the GPs were not able to have long-term experience with the PRIMA-eDS tool.
A further limitation is that we already knew due to our pilot study that the data entry into the eCRF was considered to be too time-consuming; however, we did not find any other way to circumvent it in the frame of the PRIMA-eDS project.
Data collection and analysis of the results was conducted by the research team consisting of multiple professions. Two of the interviewers were part of the PRIMA-eDS project team, which could possibly have biased the results in favour of the PRIMA-eDS tool, but we also involved one interviewer who was not involved in the PRIMA-eDS project otherwise to minimise this possible bias. Coding was done by two coders in order to enhance credibility of the findings.
Entering patient data in the eCRF is too time consuming, and thus, it is unlikely that the PRIMA-eDS tool will be adopted in daily practice as it is now. GPs were positive about the CMR as it summarises important information regarding drug-treatment and stimulates the GP to critically reflect on prescriptions. Medications were reduced to some extent. However, various barriers to deprescribing medications remain, such as that the GP and/or the patient prioritised differently, the GP regarded the medication as necessary, the GP feared that changing medication could get complex, the GP found the recommendation not applicable to the patient, and the GP did not want to interfere with medication prescribed by a colleague. Given the positive attitude towards the CMR, it seems like it is worth to develop a way for easier patient data entry or direct implementation in existing EHR, providing that the CMR proves to be effective and cost-effective.
We would like to express our gratitude to all participating GPs. Furthermore, we would like to thank Raniah El-Naggar for her support with conducting interviews.
The PRIMA-eDS study is funded by the 7th framework programme of the European Union, theme Health-2012-Innovation-1-2.2.2-2, grant agreement no. 305388–2. This additional qualitative research received funding from the internal grant program (project IFF 2015–34) of the Faculty of Health at Witten/Herdecke University, Germany.
Availability of data and materials
All transcripts of the interviews are available from the authors upon request.
AR and AS conceptualised the study. AR and CS conducted the interviews and performed the data analysis. AK provided methodological input. AR drafted the manuscript. AK, AS, and CS critically reviewed the manuscript. All authors read and approved the final manuscript.
Ethics approval and consent to participate
The study has been approved by the ethics committee of Witten/ Herdecke University in July 2015 [no: 92/2015]. Written informed consent was obtained from the participants before the start of each interview.
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
- 1.Eurostat. Population structure and ageing. 2016. http://ec.europa.eu/eurostat/statistics-explained/index.php/Population_structure_and_ageing#Further_Eurostat_information.Google Scholar
- 3.Fried TR, Tinetti ME, Iannone L. Primary care clinicians' experiences with treatment decision making for older persons with multiple conditions. Arch Intern Med. 2011;171:75–80. https://doi.org/10.1001/archinternmed.2010.318
- 12.Kaufmann CP, Tremp R, Hersberger KE, Lampert ML. Inappropriate prescribing: a systematic overview of published assessment tools. Eur J Clin Pharmacol. 2014;70:1–11. https://doi.org/10.1007/s00228-013-1575-8
- 14.Riordan DO, Walsh KA, Galvin R, Sinnott C, Kearney PM, Byrne S. The effect of pharmacist-led interventions in optimising prescribing in older adults in primary care: a systematic review. SAGE Open Med. 2016;4:2050312116652568. https://doi.org/10.1177/2050312116652568
- 15.Smith SM, Wallace E, O'Dowd T, Fortin M. Interventions for improving outcomes in patients with multimorbidity in primary care and community settings. Cochrane Database Syst Rev. 2016;3:CD006560. https://doi.org/10.1002/14651858.CD006560.pub3
- 16.Johansson T, Abuzahra ME, Keller S, Mann E, Faller B, Sommerauer C, et al. Impact of strategies to reduce polypharmacy on clinically relevant endpoints: a systematic review and meta-analysis. Br J Clin Pharmacol. 2016;82:532–48. https://doi.org/10.1111/bcp.12959.CrossRefPubMedPubMedCentralGoogle Scholar
- 25.Sönnichsen A, Trampisch US, Rieckert A, Piccoliori G, Vögele A, Flamm M, et al. Polypharmacy in chronic diseases–reduction of inappropriate medication and adverse drug events in older populations by electronic decision support (PRIMA-eDS): study protocol for a randomized controlled trial. Trials. 2016;17:1–9. https://doi.org/10.1186/s13063-016-1177-8
- 29.Malterud K, Siersma VD, Guassora AD. Sample size in qualitative interview studies: guided by information power. Qual Health Res. 2016:1753–60. https://doi.org/10.1177/1049732315617444.
- 33.Bolmsjo BB, Palagyi A, Keay L, Potter J, Lindley RI. Factors influencing deprescribing for residents in advanced care facilities: insights from general practitioners in Australia and Sweden. BMC Fam Pract. 2016;17:152. https://doi.org/10.1186/s12875-016-0551-7.CrossRefPubMedPubMedCentralGoogle Scholar
- 37.Reeve E, Thompson W, Farrell B. Deprescribing: a narrative review of the evidence and practical recommendations for recognizing opportunities and taking action. Eur J Intern Med. 2017;38:3–11. https://doi.org/10.1016/j.ejim.2016.12.021
- 38.Toth-Pal E, Wardh I, Strender L-E, Nilsson G. Implementing a clinical decision-support system in practice: a qualitative analysis of influencing attitudes and characteristics among general practitioners. Inform Health Soc Care. 2008;33:39–54. https://doi.org/10.1080/17538150801956754.CrossRefPubMedGoogle Scholar
- 40.Lugtenberg M, Weenink J-W, van der Weijden T, Westert GP, Kool RB. Implementation of multiple-domain covering computerized decision support systems in primary care: a focus group study on perceived barriers. BMC Med Inform Decis Mak. 2015;15:82. https://doi.org/10.1186/s12911-015-0205-z.CrossRefPubMedPubMedCentralGoogle Scholar
- 42.Koskela T, Sandstrom S, Makinen J, Liira H. User perspectives on an electronic decision-support tool performing comprehensive medication reviews - a focus group study with physicians and nurses. BMC Med Inform Decis Mak. 2016;16:6. https://doi.org/10.1186/s12911-016-0245-z.CrossRefPubMedPubMedCentralGoogle Scholar
- 43.Evidence-Based Medicine Guidelines. https://www.duodecim.fi/english/products/ebmg/. Accessed 30 Apr 2018.
- 44.Evidence-Based Medicine electronic Decision Support. http://www.ebmeds.org/web/guest/home?p_id=129190&b_id=129273&s_id=129273&lang=en. Accessed 30 Apr 2018.
- 45.Martinez YV, Renom-Guiteras A, Reeves D, Erandie Ediriweera de Silva R, Esmail A, Kunnamo I, et al. A set of systematic reviews to help reduce inappropriate prescribing to older people: study protocol. BMC Geriatr. 2017;17:231. https://doi.org/10.1186/s12877-017-0570-9
- 46.Renbase - Analysis of adverse drug reactions. http://www.medbase.fi/en/professionals/renbase. Accessed 30 Apr 2018.
- 47.INXBASE Interaction Database http://www.medbase.fi/en/professionals/inxbase/. Accessed 30 Apr 2018.
- 48.European Medicines Agency. http://www.ema.europa.eu/ema/. Accessed 30 Apr 2018.
- 49.RISKBASE – Analysis of adverse drug reactions. http://www.medbase.fi/en/professionals/riskbase/. Accessed 30 Apr 2018.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.